All public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 21:25, 21 May 2024 Alen Antony talk contribs created page Pegunigalsidase alfa-iwxj (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=pegunigalsidase alfa-iwxj |indicationType=treatment |indication=Fabry's disease in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis. |blackBoxWarningTitle=HYPERSENSITIVITY REACTIONS including Anaphylaxis |blackBoxWarningBody=Patients may experience hypersensitivity reaction including a...")
- 18:33, 21 May 2024 Rithish Nimmagadda talk contribs created page Vonoprazan, amoxicillin, and clarithromycin (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=vonoprazan, amoxicillin, and clarithromycin |aOrAn=a |drugClass=Potassium-competitive acid blocker |indicationType=treatment |indication=- erosive esophagitis (all grades) and relief of heartburn associated with erosive esophagitis in adults. ,Helicobacter pylori Infection |adverseReactions=-Common adverse reactions (≥2%) with vonoprazan when used for healing of erosive esophagitis: gastritis, diarrhea, abdom...")
- 16:59, 21 May 2024 Rithish Nimmagadda talk contribs created page Pirtobrutinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=pirtobrutinib |aOrAn=an |drugClass=noncovalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). |indicationType=treatment |indication=elapsed or refractory MCL in adults who have received at least 2 lines of prior systemic therapy, including a BTK inhibitor; designated an orphan drug by FDA for treatment of MCL and also in treatment of CLL or SLL in adults who have received at least 2 prior lines of th...")
- 00:09, 21 May 2024 Rithish Nimmagadda talk contribs created page Elacestrant (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro...")
- 23:07, 20 May 2024 Rithish Nimmagadda talk contribs created page Velmanase alfa-tycv (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac...")
- 20:31, 20 May 2024 Rithish Nimmagadda talk contribs created page Retifanlimab-dlwr (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue...")
- 20:18, 20 May 2024 Rithish Nimmagadda talk contribs created page Tofersen (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...")
- 16:01, 18 May 2024 Rithish Nimmagadda talk contribs created page Ritlecitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i...")
- 17:21, 17 May 2024 Rithish Nimmagadda talk contribs created page Quizartinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,...")
- 16:40, 17 May 2024 Rithish Nimmagadda talk contribs created page Lotilaner (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety...")
- 14:40, 16 May 2024 Alen Antony talk contribs created page Leniolisib (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}")
- 10:11, 16 May 2024 Muhammad Waleed talk contribs created page Avacincaptad pegol (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...")
- 09:31, 16 May 2024 Muhammad Waleed talk contribs created page File:Talvey (talquetamab-tgvs).png (image for the drug Talvey)
- 09:31, 16 May 2024 Muhammad Waleed talk contribs uploaded File:Talvey (talquetamab-tgvs).png (image for the drug Talvey)
- 07:06, 16 May 2024 Alara E. Dagsali talk contribs created page Diclofenac Patch (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...")
- 06:42, 16 May 2024 Alara E. Dagsali talk contribs created page Cortisone Acetate (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...")
- 06:32, 16 May 2024 Alara E. Dagsali talk contribs created page Clocortolone Pivalate (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...")
- 06:20, 16 May 2024 Alara E. Dagsali talk contribs created page Scorpion (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...")
- 10:58, 15 May 2024 Alara E. Dagsali talk contribs created page Lodoxamide (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...")
- 23:48, 13 May 2024 Alen Antony talk contribs created page Fezolinetant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}")
.png){kind=link}